HF
ALNY icon

HRT Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

HRT Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Buy
+4,300
New +$1.46M ﹤0.01% 1833

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's ALNY Position: Q1 2026 in Review

HRT Financial opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 128,633 shares worth $42.6M. The stake represents 0.11% of the portfolio and ranks #154 among its holdings. This is a return to the name: HRT Financial previously reported a position in ALNY as recently as Q3 2025.

HRT Financial first reported a position in ALNY in Q1 2019 and has held it in 14 quarters since. The position peaked at $133M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • HRT Financial held 128,633 shares of Alnylam Pharmaceuticals worth $42.6M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new HRT Financial position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.11% of HRT Financial's portfolio in Q1 2026, its #154 holding.
  • HRT Financial first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 14 quarters since.
  • HRT Financial's Alnylam Pharmaceuticals position peaked at $133M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.